PH12019500965A1 - Crenolab for treating flt3 mutated proliferative disorders associated mutations - Google Patents

Crenolab for treating flt3 mutated proliferative disorders associated mutations

Info

Publication number
PH12019500965A1
PH12019500965A1 PH12019500965A PH12019500965A PH12019500965A1 PH 12019500965 A1 PH12019500965 A1 PH 12019500965A1 PH 12019500965 A PH12019500965 A PH 12019500965A PH 12019500965 A PH12019500965 A PH 12019500965A PH 12019500965 A1 PH12019500965 A1 PH 12019500965A1
Authority
PH
Philippines
Prior art keywords
patient
crenolab
crenolanib
disorders associated
proliferative disorders
Prior art date
Application number
PH12019500965A
Other languages
English (en)
Inventor
Vinay K Jain
Original Assignee
Arog Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62020370&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12019500965(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arog Pharmaceuticals Inc filed Critical Arog Pharmaceuticals Inc
Publication of PH12019500965A1 publication Critical patent/PH12019500965A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH12019500965A 2016-11-02 2019-04-30 Crenolab for treating flt3 mutated proliferative disorders associated mutations PH12019500965A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662416475P 2016-11-02 2016-11-02
PCT/US2017/059377 WO2018085292A1 (en) 2016-11-02 2017-10-31 Crenolanib for treating flt3 mutated proliferative disorders associated mutations
US15/799,684 US11078541B2 (en) 2016-11-02 2017-10-31 Crenolanib for treating FLT3 mutated proliferative disorders associated mutations

Publications (1)

Publication Number Publication Date
PH12019500965A1 true PH12019500965A1 (en) 2019-12-02

Family

ID=62020370

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019500965A PH12019500965A1 (en) 2016-11-02 2019-04-30 Crenolab for treating flt3 mutated proliferative disorders associated mutations

Country Status (19)

Country Link
US (3) US11078541B2 (https=)
EP (1) EP3359155A4 (https=)
JP (3) JP2019532011A (https=)
KR (2) KR20200079351A (https=)
CN (1) CN108778276A (https=)
AU (1) AU2017353925A1 (https=)
BR (1) BR112019008762A2 (https=)
CA (1) CA3024012A1 (https=)
CL (1) CL2019001208A1 (https=)
CO (1) CO2019005466A2 (https=)
EA (1) EA201991078A1 (https=)
HK (1) HK1257195A1 (https=)
IL (1) IL266303A (https=)
MX (1) MX2019005008A (https=)
PE (1) PE20191238A1 (https=)
PH (1) PH12019500965A1 (https=)
SG (1) SG11201903889TA (https=)
WO (1) WO2018085292A1 (https=)
ZA (1) ZA201903089B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12534764B2 (en) 2016-11-02 2026-01-27 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
EA201991078A1 (ru) * 2016-11-02 2019-11-29 Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
US12268690B2 (en) 2018-07-27 2025-04-08 Oregon Health & Science University Treatments for mutations in acute myeloid leukemia
JP2022503792A (ja) * 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
CN109678849A (zh) * 2019-01-16 2019-04-26 北京悦康科创医药科技股份有限公司 一种抗癌药物的制备方法
US11471451B2 (en) * 2019-08-19 2022-10-18 Arog Pharmaceuticals, Inc. Uses of crenolanib
CN110531016B (zh) * 2019-09-05 2021-08-31 合肥诺明药物安全研究有限公司 一种hyml-122血药浓度定量分析方法
CA3186319A1 (en) * 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US11524006B2 (en) * 2020-09-17 2022-12-13 Arog Pharmaceuticals, Inc. Crenolanib for treating TRK kinase associated proliferative disorders
CN112921091B (zh) * 2021-03-16 2022-01-21 南京先声医学检验实验室有限公司 Flt3基因突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用
JP2023063189A (ja) * 2021-10-22 2023-05-09 アログ・ファーマシューティカルズ・インコーポレイテッド 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ
CN115141886B (zh) * 2022-06-28 2023-06-06 厦门艾德生物医药科技股份有限公司 一种基于高通量测序的髓系白血病基因突变检测的探针引物组及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
ATE303998T1 (de) 2000-10-17 2005-09-15 Merck & Co Inc Oral aktive salze mit tyrosinkinaseaktivität
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
DE60213842T2 (de) 2001-10-30 2007-09-06 Novartis Ag Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
EP1458713B1 (en) 2001-12-27 2005-08-24 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOCHINOLINONE AND ITS USE
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
EP1566379A4 (en) 2002-10-29 2005-11-09 Kirin Brewery CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF
SG148864A1 (en) 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
DE60326646D1 (de) 2002-12-18 2009-04-23 Vertex Pharma Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
EP1641780B1 (en) 2003-06-24 2008-11-12 Pfizer Products Incorporated Processes for the preparation of 1- [(benzoimidazole-1yl) quinolin-8-yl] piperidin-4-ylamine derivatives
WO2010117931A1 (en) * 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of treatment based on polymorphisms of the kcnq1 gene
JP2015512630A (ja) * 2012-03-12 2015-04-30 メモリアル スローン−ケタリング キャンサー センター 急性骨髄性白血病の診断、予後、及び治療用の方法及び組成物
TWI599356B (zh) 2012-09-26 2017-09-21 安羅格製藥有限責任公司 抑制突變型ｃ－ｋｉｔ的方法
BR112015016282A2 (en) * 2013-01-07 2017-07-11 Arog Pharmaceuticals, Inc. crenolanib for treatment of mutated flt3 proliferative disorders
EA201991078A1 (ru) * 2016-11-02 2019-11-29 Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3

Also Published As

Publication number Publication date
KR20200079351A (ko) 2020-07-02
CA3024012A1 (en) 2018-05-11
SG11201903889TA (en) 2019-05-30
EP3359155A4 (en) 2019-05-22
WO2018085292A1 (en) 2018-05-11
US11078541B2 (en) 2021-08-03
KR20180074792A (ko) 2018-07-03
JP7536320B2 (ja) 2024-08-20
US20250305063A1 (en) 2025-10-02
EP3359155A1 (en) 2018-08-15
BR112019008762A2 (pt) 2019-07-16
US20210324481A1 (en) 2021-10-21
ZA201903089B (en) 2019-12-18
CL2019001208A1 (es) 2019-07-26
HK1257195A1 (zh) 2019-10-18
JP2022071099A (ja) 2022-05-13
CN108778276A (zh) 2018-11-09
JP2024096859A (ja) 2024-07-17
EA201991078A1 (ru) 2019-11-29
IL266303A (en) 2019-06-30
US20180117031A1 (en) 2018-05-03
MX2019005008A (es) 2019-09-10
PE20191238A1 (es) 2019-09-11
AU2017353925A1 (en) 2018-09-27
US12404555B2 (en) 2025-09-02
CO2019005466A2 (es) 2019-07-31
JP2019532011A (ja) 2019-11-07

Similar Documents

Publication Publication Date Title
PH12019500965A1 (en) Crenolab for treating flt3 mutated proliferative disorders associated mutations
PH12015501531A1 (en) Crenolanib for treating flt3 mutated proliferative disorders
PH12016502354A1 (en) Pharmaceutical composition
PH12017502142A1 (en) Tetrasubstituted aklene compounds and their use
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MX372942B (es) Derivados de 1-(5-terc-butil-2-aril-pirazol-3-il)-3-[2-fluoro-4-[(3-oxo-4h-pirido[2,3 b]piracin-8-il)oxi]fenil]urea como inhibidores de raf para el tratamiento del cancer.
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
EP4589014A3 (en) Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden
MX377576B (es) Formulaciones de pridopidina de liberación modificada.
BR112022002609A2 (pt) Métodos de tratamento de tumores estromais gastrointestinais
MX2015012322A (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
WO2016066634A3 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
EP4285993A3 (en) Growth differentiation factor 15 as biomarker for metformin
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
CA3010708A1 (en) Methods of administering hepcidin
PH12018500003A1 (en) Treatment of patients diagnosed with pancreatic ductal adenocarcinoma
PH12015502266A1 (en) Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
PH12016502244A1 (en) Hsp70 modulators and methods for making and using the same
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
MX2015005993A (es) Composiciones y metodos para el tratamiento de displasia ectodermica.
BR112019007028A2 (pt) métodos e composições farmacêuticas para o tratamento do câncer renal
MX384453B (es) Métodos in vitro para identificar lactantes prematuros en riesgo de displasia broncopulmonar.